EUR/USD 1.17359
0.240%
Gold 3336.99
0.024%
Oil 66.781
-0.315%
USD/JPY 145.903
-0.097%
GBP/USD 1.36178
0.117%
GBP/JPY 198.693
0.065%
Browse More
  • English
  • 简体中文
  • 繁體中文
  • Tiếng Việt
  • ไทย
  • Indonesia
Subscribe
Real-time News
Samsung Electronics: It is expected that the demand for non-memory chips will gradually recover in the second half of 2025 and losses will be reduced.July 8, an EU diplomat and an EU official said that the United States has proposed a deal to the European Union that would maintain a 10% baseline tariff on all EU goods, except for sensitive industries such as aircraft and spirits. Diplomats stressed that the contours of the trade agreement are still largely a moving target and any agreement needs Trumps approval to move forward. Washington has not indicated that it will exempt politically sensitive industries such as automobiles, steel, aluminum or pharmaceuticals as requested by the EU. However, France, Italy and Ireland may be happy about the tax exemption for spirits and aircraft.Samsung Electronics: Low capacity utilization of non-memory chip business affects profitability.Samsung Electronics: Expected second quarter operating profit of 4.6 trillion won (LESG estimate: 6.2 trillion won).Samsung Electronics: Expects second quarter revenue of KRW 74 trillion (LSEG estimate: KRW 76 trillion).

Goldman Sachs Has Improved Humana's Competitive Standing

Aria Thomas

Dec 14, 2022 10:41

2.png


Goldman Sachs analysts upgraded shares of Humana (NYSE:HUM) to Buy with a $652 price target in a research note published on Tuesday.


The company's improved "competitive positioning in MA and underappreciated HC Services opportunity should outweigh the potential RADV impact," which Goldman Sachs estimates to range between $2.6 and $5.8 billion (NPV) before offsetting factors.


Analysts stated, "We see a strengthening earnings outlook as a result of improved competitive positioning in Massachusetts, which has reaccelerated member growth for 2023 and could lead to multiple years of share gains in 2024 when many competitors will face Stars headwinds." "We also see an attractive and undervalued opportunity in the health care services sector, with primary care earnings having the potential to outperform its September guidance,"


While analysts assert that the company is aware of the significant risk posed by the forthcoming RADV ruling, their EPS estimates for 2024-2025 are 4% higher than the industry average.


This reflects "3% higher member growth and a primary care EBITDA opportunity of $205mn-$395mn for 2025," which is "above the company's $100-$200mn outlook in its mid-term guidance, with more of this EBITDA hitting the P&L as WCAS centers come onto the balance sheet."


"Despite the stock's outperformance in 2022 (+18% YTD vs. MCO group +13%), the stock trades in line with its historical median despite higher forward EPS CAGR of 15% vs. its 3-year history of 12%," concluded the analysts.

Suggestion